{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:57:52Z","timestamp":1778338672739,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.pupt.2017.12.005","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T03:24:52Z","timestamp":1513653892000},"page":"11-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"49","author":[{"given":"James F.","family":"Donohue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-7450","authenticated-orcid":false,"given":"Christian","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Marvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Patalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1441-0962","authenticated-orcid":false,"given":"Robert","family":"Fogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2017.12.005_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/ers.13.18","article-title":"Which is the optimal bronchodilator therapy for chronic obstructive pulmonary disease?","volume":"7","author":"Baloira","year":"2013","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. [http:\/\/www.goldcopd.com]."},{"key":"10.1016\/j.pupt.2017.12.005_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1465-9921-14-49","article-title":"Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease","volume":"14","author":"Tashkin","year":"2013","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2017.12.005_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4104\/pcrj.2012.00092","article-title":"Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD","volume":"22","author":"Price","year":"2013","journal-title":"Prim. Care Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1513\/pats.200701-024FM","article-title":"Inhaled corticosteroids in chronic obstructive pulmonary disease","volume":"4","author":"Suissa","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.pupt.2017.12.005_bib6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1183\/09031936.06.00145104","article-title":"Outcomes and markers in the assessment of chronic obstructive pulmonary disease","volume":"27","author":"Jones","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/thorax.56.11.880","article-title":"Health status measurement in chronic obstructive pulmonary disease","volume":"56","author":"Jones","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2017.12.005_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2125.2005.02400.x","article-title":"Quantifying bronchodilator responses in chronic obstructive pulmonary disease trials","volume":"59","author":"Lavorini","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pupt.2017.12.005_bib9","author":"Chronic Obstructive Pulmonary Disease"},{"key":"10.1016\/j.pupt.2017.12.005_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1513\/pats.200512-126SF","article-title":"Health status: what does it mean for payers and patients?","volume":"3","author":"Jones","year":"2006","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.pupt.2017.12.005_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1183\/09031936.00021707","article-title":"Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes","volume":"30","author":"Young","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-12-40","article-title":"Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review","volume":"12","author":"Westwood","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2017.12.005_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib15","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","article-title":"Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study","volume":"102","author":"Vogelmeier","year":"2008","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/15412550902724073","article-title":"Formoterol and tiotropium compared with tiotropium alone for treatment of COPD","volume":"6","author":"Tashkin","year":"2009","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2017.12.005_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1465-9921-12-161","article-title":"Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis","volume":"12","author":"Jones","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2017.12.005_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2017.12.005_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/COPD-200050666","article-title":"The MCID of the transition dyspnea index is a total score of one unit","volume":"2","author":"Mahler","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2017.12.005_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Software"},{"key":"10.1016\/j.pupt.2017.12.005_bib22","series-title":"Linear Mixed-effects Models using Eigen and S4 R Package","author":"Bates","year":"2015"},{"key":"10.1016\/j.pupt.2017.12.005_bib23","unstructured":"Least-Squares Means R package [http:\/\/CRAN.R-project.org\/package=lsmeans]."},{"key":"10.1016\/j.pupt.2017.12.005_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/1467-985X.00164","article-title":"Correcting for regression dilution bias: comparison of methods for a single predictor variable","volume":"163","author":"Frost","year":"2000","journal-title":"JR. Stat. Soc. A"},{"key":"10.1016\/j.pupt.2017.12.005_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1183\/09031936.06.00055805","article-title":"Predictors of COPD symptoms: does the sex of the patient matter?","volume":"28","author":"Watson","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/15412555.2010.528812","article-title":"Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients","volume":"7","author":"Van de Maele","year":"2010","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2017.12.005_bib27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/thx.2010.139113","article-title":"QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease","volume":"65","author":"van Noord","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2017.12.005_bib28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","article-title":"Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study","volume":"42","author":"Bateman","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib29","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.rmed.2013.05.016","article-title":"Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study","volume":"107","author":"Dahl","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(12)70052-8","article-title":"Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study","volume":"1","author":"Vogelmeier","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1465-9921-14-100","article-title":"Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis","volume":"14","author":"Cope","year":"2013","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2017.12.005_bib33","first-page":"2","article-title":"Pharmacology of novel treatments for COPD: are fixed dose combination LABA\/LAMA synergistic?","author":"Spina","year":"2015","journal-title":"Eur. Clin. Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib34","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2017.12.005_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2466-10-11","article-title":"Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study","volume":"10","author":"Feldman","year":"2010","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1465-9921-12-156","article-title":"Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial","volume":"12","author":"D'Urzo","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2017.12.005_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium","volume":"182","author":"Donohue","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1378\/chest.10-1830","article-title":"Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study","volume":"140","author":"Chapman","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2017.12.005_bib39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.rmed.2011.02.008","article-title":"Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study","volume":"105","author":"Korn","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib40","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1183\/09031936.00191810","article-title":"Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD","volume":"38","author":"Buhl","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib41","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.clinthera.2011.11.009","article-title":"Efficacy and tolerability of indacaterol 75 mug once daily in patients aged >\/=40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies","volume":"33","author":"Kerwin","year":"2011","journal-title":"Clin Ther."},{"key":"10.1016\/j.pupt.2017.12.005_bib42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/15412555.2012.729623","article-title":"Efficacy of indacaterol 75 mug once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies","volume":"9","author":"Gotfried","year":"2012","journal-title":"COPD"},{"key":"10.1016\/j.pupt.2017.12.005_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1440-1843.2011.02107.x","article-title":"Efficacy and safety of indacaterol 150 and 300 microg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study","volume":"17","author":"Kinoshita","year":"2012","journal-title":"Respirology"},{"key":"10.1016\/j.pupt.2017.12.005_bib45","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.12.005_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2466-14-4","article-title":"A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study","volume":"14","author":"Chapman","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.pupt.2017.12.005_bib48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/COPD.S51592","article-title":"Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study","volume":"9","author":"Vincken","year":"2014","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.pupt.2017.12.005_bib49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/resp.12211","article-title":"Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study","volume":"19","author":"Yao","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.pupt.2017.12.005_bib50","first-page":"57","article-title":"Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study","volume":"10","author":"Wang","year":"2015","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.pupt.2017.12.005_bib51","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1164\/rccm.201505-1048OC","article-title":"FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol\/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease","volume":"192","author":"Mahler","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917302377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917302377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T14:29:50Z","timestamp":1533133790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553917302377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":51,"alternative-id":["S1094553917302377"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2017.12.005","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2017.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}